Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Estera Okon

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Cells|April 12, 2022
Assessment of Pharmacological Interactions between SIRT2 Inhibitor AGK2 and Paclitaxel in Different Molecular Subtypes of Breast Cancer CellsAnna Wawruszak, Jarogniew Luszczki, Arkadiusz Czerwonka, et al.
Pharmacological Reports : PR|July 28, 2022
Additive pharmacological interaction between sirtuin inhibitor cambinol and paclitaxel in MCF7 luminal and MDA-MB-231 triple-negative breast cancer cellsAnna Wawruszak, Estera Okon, Ilona Telejko, et al.
International Journal of Molecular Sciences|June 24, 2022
Antagonistic Pharmacological Interaction between Sirtuin Inhibitor Cambinol and Paclitaxel in Triple-Negative Breast Cancer Cell Lines: An Isobolographic AnalysisAnna Wawruszak, Jarogniew Luszczki, Estera Okon, et al.
Cancers|July 24, 2021
Valproic Acid and Breast Cancer: State of the Art in 2021Anna Wawruszak, Marta Halasa, Estera Okon, et al.
International Journal of Molecular Sciences|February 22, 2020
Advances in Chemistry and Bioactivity of Magnoflorine and Magnoflorine-Containing ExtractsEstera Okon, Wirginia Kukula-Koch, Agata Jarzab, et al.
Cancers|September 28, 2021
Vorinostat (SAHA) and Breast Cancer: An OverviewAnna Wawruszak, Lidia Borkiewicz, Estera Okon, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|February 12, 2025
Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studiesAnna Wawruszak, Jarogniew Luszczki, Damian Bartuzi, et al.
International Journal of Molecular Sciences|November 14, 2023
Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast CancerEstera Okon, Katarzyna Gaweł-Bęben, Agata Jarzab, et al.
International Journal of Molecular Sciences|June 2, 2021
Sensitization of MCF7 Cells with High Notch1 Activity by Cisplatin and Histone Deacetylase Inhibitors Applied TogetherAnna Wawruszak, Jarogniew Luszczki, Marta Halasa, et al.
Molecules (Basel, Switzerland)|November 14, 2023
Emodin-8-<i>O</i>-Glucoside-Isolation and the Screening of the Anticancer Potential against the Nervous System TumorsEstera Okon, Maryna Koval, Anna Wawruszak, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Cells|April 12, 2022
Assessment of Pharmacological Interactions between SIRT2 Inhibitor AGK2 and Paclitaxel in Different Molecular Subtypes of Breast Cancer CellsAnna Wawruszak, Jarogniew Luszczki, Arkadiusz Czerwonka, et al.
Pharmacological Reports : PR|July 28, 2022
Additive pharmacological interaction between sirtuin inhibitor cambinol and paclitaxel in MCF7 luminal and MDA-MB-231 triple-negative breast cancer cellsAnna Wawruszak, Estera Okon, Ilona Telejko, et al.
International Journal of Molecular Sciences|June 24, 2022
Antagonistic Pharmacological Interaction between Sirtuin Inhibitor Cambinol and Paclitaxel in Triple-Negative Breast Cancer Cell Lines: An Isobolographic AnalysisAnna Wawruszak, Jarogniew Luszczki, Estera Okon, et al.
Cancers|July 24, 2021
Valproic Acid and Breast Cancer: State of the Art in 2021Anna Wawruszak, Marta Halasa, Estera Okon, et al.
International Journal of Molecular Sciences|February 22, 2020
Advances in Chemistry and Bioactivity of Magnoflorine and Magnoflorine-Containing ExtractsEstera Okon, Wirginia Kukula-Koch, Agata Jarzab, et al.
Cancers|September 28, 2021
Vorinostat (SAHA) and Breast Cancer: An OverviewAnna Wawruszak, Lidia Borkiewicz, Estera Okon, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|February 12, 2025
Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studiesAnna Wawruszak, Jarogniew Luszczki, Damian Bartuzi, et al.
International Journal of Molecular Sciences|November 14, 2023
Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast CancerEstera Okon, Katarzyna Gaweł-Bęben, Agata Jarzab, et al.
International Journal of Molecular Sciences|June 2, 2021
Sensitization of MCF7 Cells with High Notch1 Activity by Cisplatin and Histone Deacetylase Inhibitors Applied TogetherAnna Wawruszak, Jarogniew Luszczki, Marta Halasa, et al.
Molecules (Basel, Switzerland)|November 14, 2023
Emodin-8-<i>O</i>-Glucoside-Isolation and the Screening of the Anticancer Potential against the Nervous System TumorsEstera Okon, Maryna Koval, Anna Wawruszak, et al.
Pageof 2